ArticleInternal medicine (Tokyo, Japan)2020

Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis.

Hiroshi Miyawaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.